Former Allergan Exec Carrie Strom Named CEO of Hugel Following U.S. Launch of Letybo

Carrie Strom, the former vice president of Allergan Aesthetics, has been appointed as president and CEO of Hugel, the South Korea-based brand that manufactures Letybo, a botulinum toxin injectable. This transition, as of Oct. 13, follows Hugel’s rollout of Letybo in the U.S. in May 2025. 

Prior to Strom’s appointment, between May 2020 and February 2025, she served as the vice president for Allergan, the manufacturers of Botox, per an Oct. 13 press release. Before Strom claimed the position as CEO, her predecessor was Ji-hoon Sohn, the former CEO. 

Former Allergan Aesthetics VP Carrie Strom steps in as Hugel’s new CEO, marking a pivotal leadership transition.Courtesy of Hugel Oct. 13 Press Release"I am honored to join Hugel as the CEO and look forward to working alongside the talented and dedicated employees, operating team and board of directors," said Strom. 

Hugel, who also produces other injectables, including hyaluronic acid fillers and skin boosters, as well as absorbable sutures, exosomes and skincare [1], initially launched Letybo in South Korea in 2016. Before its rollout in the U.S in mid-2025, the injectable was FDA approved in 2024.

Approved in  the US, China and Europe, Letybo is now available in 69 countries, and its dermal fillers sold in 53 countries. As Letybo freshly integrates into the U.S aesthetics market, the recent appointment of Strom as CEO marks a strategic move to accelerate Hugel’s growth and presence in this region.

"Ms. Strom is a proven enterprise leader who we are confident will lead Hugel to the next level," said Suk Cha, chairman of the Hugel board of directors. "We look forward to accelerating our expansion in the Americas and other key global markets under her leadership."

References: 

1- https://www.medestheticsmag.com/treatments/article/22941215/with-fda-approval-kbeauty-letybo-brings-highpurity-botulinum-toxin-a-to-us-injectable-market